Home » FDA APPROVES TEVA'S GENERIC UNIRETIC
FDA APPROVES TEVA'S GENERIC UNIRETIC
Teva Pharmaceutical Industries announced that the FDA has approved its abbreviated new drug application for moexipril HCl/hydrochlorothiazide tablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg. The company said it would begin shipping the products immediately.
The drug is the first AB-rated generic equivalent of Schwarz Pharma's Uniretic, which is indicated for the treatment of hypertension, Teva said.
The brand product has annual sales of approximately $30 million in the U.S., according to Teva.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct